key: cord-353392-rqeultbq
authors: Kumar, Govindarajan Venkat; Jeyanthi, Venkadapathi; Ramakrishnan, Saminathan
title: A short review on antibody therapy for COVID-19
date: 2020-04-20
journal: New Microbes New Infect
DOI: 10.1016/j.nmni.2020.100682
sha: 
doc_id: 353392
cord_uid: rqeultbq

Abstract The beginning of the novel SARS-CoV-2 human coronavirus in Wuhan, China, has triggered a worldwide respiratory disease outbreak (COVID-19). By April 07, 2020, SARS-CoV-2 has affected more than 1.36 million people worldwide and caused more than 75,900 deaths. To date, the anti-malaria drug hydroxychloroquine found to be a treatment option for SARS-CoV-2. In addition to supportive treatment, such as oxygen supply in moderate cases and extracorporeal membrane oxygenation in critically ill patients, unique medications for this condition are also under investigation. Here we reviewed the antibody therapy might be an immediate strategy for emergency prophylaxis and SARS-CoV-2 therapy.

The coronavirus is a family of viruses that can cause a range of illnesses in humans with the common cold and more severe forms like Severe Acute Respiratory Syndrome (SARS) and

Middle East Respiratory Syndrome (MERS) which are dangerous. The first identified severe infection caused by a coronavirus arose with the 2003 SARS epidemic in China [1, 2] . A second outbreak of severe infection began in 2012 in Saudi Arabia with the MERS [3, 4] . The third outbreak of severe illness caused by the novel SARS-CoV-2 coronavirus (COVID-19) that emerged in the Wuhan city, China, is pandemic and spread to more than 200 countries [5, 6, 7] .

More than half a million people worldwide have been infected by the novel SARS-CoV-2 coronavirus. As of 07 April 2020, there have been at least 75,900 confirmed deaths and more than 1.36 million affected people worldwide [7] . Every hour the numbers have been increasing, with the United States recording the maximum positive cases in the world. Italy, Spain, Germany, France in Europe continue to be the most affected, with more than 16,000, 13000, 1000 and 8,000 deaths respectively till April 7, 2020 [7] . Currently, the anti-malaria drug hydroxychloroquine found to be a treatment option for COVID-19. A non-randomized study in a small sample size from France shows that the hydroxychloroquine plus azithromycin treatment reduced the viral load in COVID-19 patients [8] . Following this study, another group from France reported that the hydroxychloroquine plus azithromycin have no strong antiviral activity in severely affected COVID-19 patients [9] . Clinical studies from China show that the hydroxychloroquine reduced the risk of progression to severe illness in COVID-19 patients [10, 11] . Chloroquine and hydroxychloroquine are highly toxic in overdose, leading to the rapid onset of central nervous system toxicity (seizures and coma) and cardiovascular failure [12] .

Hydroxychloroquine received an emergency use authorization from the FDA as of 3 April 2020, but there are still a lot of questions about optimal doses and treatments for COVID-19.

Coronavirus virions are spherical with a diameter of approximately 125 nm as revealed by cryo-electron tomography and cryo-electron microscopy [13] . The corona viral genome encodes four main structural proteins namely the surface spike (S) glycoprotein, the membrane (M) protein, the small envelope (E) glycoprotein, and the nucleocapsid (N) protein. All these proteins are required to provide the structure of complete viral particles called virion [14, 15] .

The spike protein is ~180KD glycoprotein which is present on the surface of the virus. It is crucial for the entry of coronavirus into the host cell. It contains two subunits namely S1and S2.

The S1 subunit binds to the receptor on the surface of the host cell whereas S2 subunit mediates the cell membrane fusion [15, 16] .

Major research has focused on identifying antibody molecules targeting spike proteins as WuXi Biologics, to develop serum therapy that could be useful as first aid for high-risk patients.

In this mini-review, we highlight the therapeutic intervention that may have the potential for prophylaxis and SARS-CoV-2 therapy.

Convalescent plasma therapy can be considered as one of the way to control the SARS-CoV-2 pandemic. Researchers suggest that this technique is decades old approach which was used early 1930s and the theory is simple. The person who has recovered from viral infection blood is collected and serum is separated. The serum which contains antigen raised antibodies was injected into a newly infected person to combat the virus antigen. Antibodies are proteins that are produced by B cells of the immune system. They are able to bind to "Antigen" a specific molecule present on the pathogen that invades the Human system and directly neutralizes or activates an immune response [17, 18] . Based on the previous studies and reports in treating other coronaviruses such as SARS and MERS, the early administration of convalescent plasma from patients that contains raised antibodies can possibly reduce the spreading of infection and mortality [19, 20, 21, 22] . Shen et al. reported that the convalescent plasma transfusion may be beneficial in the treatment of critically ill patients with SARS-CoV-2 infections. After getting approval from the ethical committee, Shenzhen, Third People's Hospital, they administrated convalescent plasma containing neutralizing antibodies to 5 critically ill patients with SARS-CoV-2. Among those 3 patients discharged from the hospital and 2 patients under an incubation period of 37 days [23] . Casadevall and Pirofski highlighted the risks of passive administration of convalescent sera, which falls into two categories, serum disease and antibody-dependent enhancement of infection. Serum disease is those associated with the transmission of other blood infections, whereas the antibody-dependent enhancement is the theoretical concern that antibodies to one form of coronavirus could enhance infection to another viral strain [24] . Hence, it is important to identify the human monoclonal antibody that neutralizes SARS-CoV-2. Those cross-neutralizing antibodies can target a common epitope on these viruses and offers potential for the prevention and treatment of COVID-19.

Targeting the trimeric spike (S) glycoproteins on the SARS-CoV-2 surface that mediate Research reports stating that the SARS-CoV-2 RBD exhibited a significantly higher binding affinity to the ACE2 receptor than SARS-CoV RBD. This could block the binding of SARS-CoV-2 RBD to ACE2-expressing cells, thus constraining their infection to host cells [26] . Yushun Wan and his colleagues also reported that the sequence of SARS-CoV-2 which is similar to SARS-CoV, including its receptor-binding motif (RBM) that directly contacts ACE2, strongly signifying that SARS-CoV-2 uses ACE2 as its receptor [27] . Andersen (human) monoclonal antibody that neutralizes SARS-CoV-2. Research reports declaring that the 47D11 binds a conserved epitope on the spike receptor-binding domain and cross-neutralize SARS-CoV-2. The cross-reactive nature of 47D11 shows that the antibody is more possible to target the conserved core structure of the S1B receptor binding domain. Hence these neutralizing antibodies can reduce the course of virus action in the host or defend an uninfected host that is exposed to the virus [33] . Therefore, targeting the RBD amino acid in SARS-CoV-2 treatment will help scientists to develop effective therapeutic agents to treat and prevent this infection.

Amino acid mutations and recombination in RBD of different host coronaviruses are considered to be associated with host adaptation and infection across species. Recent research indicates that recombination and insertion of a cleavage site in the RBD may increase the infectivity and replication capacity of the virus [34] . Ou et al. analyzed RBD mutation worldwide and reported 10 mutants identified under high positive selection pressure during spread. They investigated the SARS-Cov-2 isolates collected from different parts of the world and compared the RBD mutations with the prototype Wuhan-Hu-1 strain. They identified that the two groups of amino acid mutations in the SARS-CoV-2 RBD domain: the "similar affinity" group (F342L, R408I) and the "higher affinity" group (N354D D364Y, V367F, W436R). The "higher affinity" group RBD mutations under the positive selective pressure enhanced the infection efficiency of the SARS-CoV-2 [35] . Hence, epidemiology data and mutation surveillance are very important to reveal more exact spreading routes of the pandemic SARS-CoV-2. Further, the RBD mutated strains in other countries need great consideration to find the therapeutic.

In conclusion, it is very essential to isolate the raised antibodies by SARS-CoV-2 disease recovered patient's regional wise. Raised antibodies should be produced on a large scale for the treatment of SARS-CoV-2 patients. These antibodies could provide an immediate strategy for emergency prophylaxis and SARS-CoV-2 therapy, while alternative and more time-consuming development of vaccines and new drugs are underway. As a result, SARS-CoV-2 neutralizing antibodies may be used to prevent infection in people exposed to SARS-CoV-2, such as hospital staff caring for suspected SARS-CoV-2 patients, and may also be used for early treatment of infected individuals to prevent the onset of serious SARS-CoV-2 disease and to reduce the chance of spreading the virus to exposed individuals.

The origin, transmission and clinical therapies on coronavirus disease 2019 (COVID-19) outbreak -an update on the status

Coronavirus Infections-More Than Just the Common Cold

Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study

SARS and other coronaviruses as causes of pneumonia

The proximal origin of SARS-CoV-2

COVID-19: a novel zoonotic disease caused by a coronavirus from China: what we know and what we don't

Coronavirus COVID-19 Global Cases by the

Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial

No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infection

A pilot study of hydroxychloroquine sulfate in patients with common 2019 coronavirus disease-19 (COVID-19)

Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial

Toxicokinetics of hydroxychloroquine following a massive overdose

Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation

Coronavirus envelope protein: current knowledge

A pneumonia outbreak associated with a new coronavirus of probable bat origin

A new coronavirus associated with human respiratory disease in China

Convalescent plasma as a potential therapy for COVID-19

Convalescent plasma therapy for persistent hepatitis E virus infection

Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) -possible lessons from a systematic review of SARS-CoV therapy

Feasibility of a randomized controlled trial to assess treatment of Middle East Respiratory Syndrome Coronavirus (MERS-CoV) infection in Saudi Arabia: a survey of physicians

Use of convalescent plasma therapy in SARS patients in Hong Kong

Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS patients

Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma

The convalescent sera option for containing COVID19

Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein

Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine

Receptor recognition by novel coronavirus from Wuhan: An analysis based on decade-long structural studies of SARS

SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease Inhibitor

Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV

Potent neutralization of severe acute respiratory syndrome (SARS) coronavirus by a human mAb to S1 protein that blocks receptor association

Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of Severe acute respiratory syndrome coronavirus

Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody

A human monoclonal antibody blocking SARS-CoV-2 infection. bioRxiv

Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding

RBD mutations from circulating SARS-CoV-2 strains enhance the structure stability and infectivity of the spike protein